<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">LEVOMETHADYL ACETATE HYDROCHLORIDE</span><br/>(lev-o-meth'a-dil)<br/><span class="topboxtradename">Orlaam<br/></span><b>Classifications:</b> <span class="classification">central nervous system agent</span>; <span class="classification">narcotic agonist analgesic</span>; <span class="classification">opioid detoxification agent</span><br/><b>Prototype: </b>Morphine<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>10 mg/mL oral solution</p>
<h1><a name="action">Actions</a></h1>
<p>Used as a cross-substitute for morphine-like agents, including heroin, because its actions/pharmacologic effects are similar
         to those opioid analgesics. Tolerance to the analgesic and sedative effects of levomethadyl occurs with prolonged usage.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Provides a long duration of action as a synthetic opioid analgesic (methadone derivative).</p>
<h1><a name="uses">Uses</a></h1>
<p>Management of opiate dependence.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to levomethadyl, lactation, pregnancy (category C).</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Concurrent use of other CNS depressants, renal or hepatic insufficiency, older adults, cardiac disease or hypertension, head
         injury or increased intracranial pressure, respiratory disorders (asthma, cor pulmonale, COPD), hypothyroidism, Addison's
         disease, prostatic hypertrophy, acute abdomen, anesthesia, previous hypersensitivity to methadone or other opioids. Safety
         and effectiveness in children 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Opiate Detoxification</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 2040 mg diluted in liquid q4872h, may be adjusted by 510 mg in 1- to 2-wk intervals (doses have ranged from
               10 to 140 mg 3 times/wk)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Do not give daily doses; recommended doses are intended for q.o.d./q3d dosing only; daily use will lead to serious and potentially
            fatal overdose.
         </li>
<li>Treatment of overdose: Cautiously give naloxone beginning with small doses of 0.10.2 mg; increase if needed at 2- to
            3-min intervals (max: of 10 mg). Keep under prolonged observation following initial reversal; levomethadyl has longer duration
            of action than naloxone.
         </li>
<li>See manufacturer's guidelines for reinduction following a lapse of one or more doses.</li>
<li>Protect from direct light.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Withdrawal reactions (nasal congestion, abdominal symptoms, diarrhea, muscle aches, anxiety); asthenia, arthralgia, back pain,
      chills, edema, hot flashes (especially males), flu syndrome, <span class="speceff-common">malaise,</span> cough, rhinitis, yawning, rash, <span class="speceff-common">sweating</span>. <span class="typehead">CV:</span> Prolonged QTc interval leading to severe arrhythmias. <span class="typehead">CNS:</span> Abnormal dreams, anxiety, decreased libido, depression, euphoria, headache, <span class="speceff-common">insomnia, nervousness,</span> somnolence. <span class="typehead">GI:</span> <span class="speceff-common">Abdominal pain, constipation.</span> diarrhea, dry mouth, nausea, vomiting. <span class="typehead">Special Senses:</span> Blurred vision. <span class="typehead">Urogenital:</span> <span class="speceff-common">Difficult ejaculation, impotence</span>. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <span class="classification">narcotic antagonists</span> <b>(naloxone,</b> <b>naltrexone)</b> or <span class="classification">partial antagonists</span> <b>(buprenorphine,</b> <b>butorphanol,</b> <b>nalbuphine,</b> <b>pentazocine)</b> can induce withdrawal symptoms. <b>Carbamazepine,</b> <b>phenobarbital,</b> <b>phenytoin,</b> <b>rifabutin,</b> <b>rifampin</b> may increase peak activity or shorten the duration of action of levomethadyl. <b>Cimetidine,</b> <b>erythromycin,</b> <b>ketoconazole</b> may slow onset, lower activity, or increase duration of action of levomethadyl. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly absorbed from GI tract. <span class="typehead">Onset:</span> 1530 min. <span class="typehead">Peak:</span> 1.52 h. <span class="typehead">Duration:</span> 4872 h. <span class="typehead">Distribution:</span> Approximately 80% protein bound, crosses placenta. <span class="typehead">Metabolism:</span> Extensive first-pass metabolism to active metabolite, norlaam. <span class="typehead">Elimination:</span> 72% eliminated in urine. <span class="typehead">Half-Life:</span> 2.6 d. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor carefully throughout induction period for overdose and respiratory depression.</li>
<li>Dosage adjustment is complex due to delayed onset of action; monitor for excessive opioid effect (i.e., sedation, incoordination,
            orthostatic hypotension).
         </li>
<li>Monitor for and report S&amp;S of withdrawal during interdose periods; changes in dosing may be needed.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Full effect of drug requires 710 d. Avoid abuse of psychoactive drugs and alcohol, especially during initial induction
            period; may potentiate drug effect.
         </li>
<li>Learn common adverse effects and possible drug interactions.</li>
<li>Do not drive or engage in other potentially hazardous activities until response to drug is known.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>